NCT03092180 Optimizing Treatment on Idiopathic Inflammatory Myopathies
| NCT ID | NCT03092180 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Sao Paulo |
| Condition | Idiopathic Inflammatory Myopathies |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2005-01 |
| Primary Completion | 2024-05-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2005-01 with a primary completion date of 2024-05-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset. This scheme is an internal routine protocol of our Service.
Eligibility Criteria
Inclusion Criteria: * Idiopathic inflammatory myopathies Exclusion Criteria: * Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies
Contact & Investigator
Samuel K Shinjo, PhD
PRINCIPAL INVESTIGATOR
Universidade de Sao Paulo - Rheumatology Division
Frequently Asked Questions
Who can join the NCT03092180 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Inflammatory Myopathies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03092180 currently recruiting?
Yes, NCT03092180 is actively recruiting participants. Contact the research team at samuel.shinjo@gmail.com for enrollment information.
Where is the NCT03092180 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT03092180 clinical trial?
NCT03092180 is sponsored by University of Sao Paulo. The principal investigator is Samuel K Shinjo, PhD at Universidade de Sao Paulo - Rheumatology Division. The trial plans to enroll 60 participants.